Efficacy of Definitive Radiotherapy for Patients with Clinical Stage IIIB or IIIC Lung Adenocarcinoma and Epidermal Growth Factor Receptor (EGFR) Mutations Treated Using First- or Second-Generation EGFR Tyrosine Kinase Inhibitors
Table 2
Characteristics of patients included in the first supplementary analysis.
RT group (n = 36)
Non-RT group (n = 36)
Number or mean (SD)†
(%)†
Number or mean (SD)†
(%)†
Standardized difference†
Age (years)
63.19 (8.56)
63.00 (6.09)
0.243
Sex
Female
20
(56)
21
(58)
0.056
Male
16
(44)
15
(42)
Residency
Non-northern
21
(58)
23
(64)
0.114
Northern
15
(42)
13
(36)
Comorbidity
<1
‡
‡
‡
‡
0.244
≥1
‡
‡
‡
‡
BMI (kg/m2)
23.98 (3.31)
24.70 (3.02)
0.228
Social-economic status
Minimum wage or lower
9
(25)
7
(19)
0.134
Higher
27
(75)
29
(81)
Smoking
No
24
(67)
26
(72)
0.121
Yes
12
(33)
10
(28)
Clinical T-stage
T1–T2
16
(44)
15
(42)
0.056
T3–T4
20
(56)
21
(58)
Clinical N-stage
N0–N2
7
(19)
7
(19)
0.056
N3
29
(81)
29
(81)
Tumor size (mm)
45.39 (18.90)
45.28 (22.82)
0.005
ECOG PS
0-1
‡
‡
‡
‡
0.109
2
‡
‡
‡
‡
BMI, body mass index; ECOG PS, eastern cooperative oncology group performance status; PS, propensity score; RT, radiotherapy; SD, standard deviation. †Rounded. ‡The exact numbers are not reported because of a Health and Welfare Data Science Center (HWDC) database center policy to avoid numbers ≤2 in single cells.
